These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 18382427)
21. High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. Stemmler HJ; Kahlert S; Brudler O; Beha M; Müller S; Stauch B; Heinemann V Clin Oncol (R Coll Radiol); 2005 Dec; 17(8):630-5. PubMed ID: 16372489 [TBL] [Abstract][Full Text] [Related]
22. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Shelley M; Cleves A; Wilt TJ; Mason M Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413 [TBL] [Abstract][Full Text] [Related]
23. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457 [TBL] [Abstract][Full Text] [Related]
24. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059 [TBL] [Abstract][Full Text] [Related]
25. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC. Lee Y; Kim YS; Hong B; Cho YM; Lee JL J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088 [TBL] [Abstract][Full Text] [Related]
26. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial. Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900 [TBL] [Abstract][Full Text] [Related]
27. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens. Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060 [TBL] [Abstract][Full Text] [Related]
28. Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Hamm JT; Wilson JW; Rastogi P; Lembersky BC; Tseng GC; Song YK; Kim W; Robidoux A; Raymond JM; Kardinal CG; Shalaby IA; Ansari R; Paik S; Geyer CE; Wolmark N; Clin Breast Cancer; 2008 Jun; 8(3):257-63. PubMed ID: 18650156 [TBL] [Abstract][Full Text] [Related]
29. Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study. Estévez LG; Sánchez-Rovira P; Dómine M; León A; Calvo I; Jaén A; Casado V; Rubio G; Daz M; Miró C; Lobo F Semin Oncol; 2004 Apr; 31(2 Suppl 5):31-6. PubMed ID: 15199530 [TBL] [Abstract][Full Text] [Related]
30. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Schmid P; Krocker J; Jehn C; Michniewicz K; Lehenbauer-Dehm S; Eggemann H; Heilmann V; Kümmel S; Schulz CO; Dieing A; Wischnewsky MB; Hauptmann S; Elling D; Possinger K; Flath B Ann Oncol; 2005 Oct; 16(10):1624-31. PubMed ID: 16030028 [TBL] [Abstract][Full Text] [Related]
32. A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes. Kohail H; Shehata S; Mansour O; Gouda Y; Gaafar R; Hamid TA; El Nowieam S; Al Khodary A; El Zawahry H; Wareth AA; Halim IA; Taleb FA; Hamada E; Barsoum M; Abdullah M; Meshref M Hematol Oncol Stem Cell Ther; 2012; 5(1):42-8. PubMed ID: 22446614 [TBL] [Abstract][Full Text] [Related]
33. Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension. He J; Ying W; Yang H; Xu X; Shao W; Guan Y; Jiang M; Wu Y; Zhong B; Wang D; Tucker S; Zhong N Anticancer Drugs; 2009 Oct; 20(9):838-44. PubMed ID: 19668080 [TBL] [Abstract][Full Text] [Related]
34. Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: a phase II study. Aydiner A; Kiyik M; Cikrikcioglu S; Kosar F; Gurses A; Turna A; Yazar A; Dilege S; Goksel T; Cakan A Lung Cancer; 2007 Nov; 58(2):246-52. PubMed ID: 17683827 [TBL] [Abstract][Full Text] [Related]
35. Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience. Martin-Romano P; Baraibar I; Espinós J; Legaspi J; López-Picazo JM; Aramendía JM; Fernández OA; Santisteban M Breast J; 2018 Jul; 24(4):473-479. PubMed ID: 29286192 [TBL] [Abstract][Full Text] [Related]
36. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. Airoldi M; Cattel L; Passera R; Pedani F; Delprino L; Micari C Am J Clin Oncol; 2006 Oct; 29(5):490-4. PubMed ID: 17023785 [TBL] [Abstract][Full Text] [Related]
37. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial. Burch PA; Mailliard JA; Hillman DW; Perez EA; Krook JE; Rowland KM; Veeder MH; Cannon MW; Ingle JN Am J Clin Oncol; 2005 Apr; 28(2):195-200. PubMed ID: 15803016 [TBL] [Abstract][Full Text] [Related]
38. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE; Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978 [TBL] [Abstract][Full Text] [Related]
39. Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. Adamo V; Lorusso V; Rossello R; Adamo B; Ferraro G; Lorusso D; Condemi G; Priolo D; Di Lullo L; Paglia A; Pisconti S; Scambia G; Ferrandina G Br J Cancer; 2008 Jun; 98(12):1916-21. PubMed ID: 18493232 [TBL] [Abstract][Full Text] [Related]
40. Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer. Stemmler HJ; diGioia D; Freier W; Tessen HW; Gitsch G; Jonat W; Brugger W; Kettner E; Abenhardt W; Tesch H; Hurtz HJ; Rösel S; Brudler O; Heinemann V Br J Cancer; 2011 Mar; 104(7):1071-8. PubMed ID: 21407218 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]